Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Cephalalgia ; 26(5): 537-47, 2006 May.
Article in English | MEDLINE | ID: mdl-16674762

ABSTRACT

A randomized, controlled, cross-over trial compared single doses of 50 mg diclofenac potassium sachets and tablets with placebo in 328 patients with migraine pain, treating 888 attacks. For the primary endpoint 24.7% of the patients were pain free at 2 h postdose with sachets, 18.5% for tablets and 11.7% for placebo. Treatment differences were significant for sachets vs. placebo (P<0.0001), tablets vs. placebo (P=0.0040) and for sachets vs. tablets (P=0.0035). The numbers needed to treat compared with placebo to achieve pain free at 2 h were 7.75 [95% confidence interval (CI) 5.46, 13.35] for sachets and 15.83 (95% CI 8.63, 96.20) for tablets. Sachets were also statistically superior to tablets for sustained headache response, sustained pain free and reduction in headache intensity within the first 2 h postdose measured on a visual analogue scale (P<0.05). Onset of analgesic effect was 15 min for sachets and 60 min for tablets. Fewer patients needed rescue medication, and there were marked improvements in accompanying symptoms and working ability with both sachets and tablets vs. placebo. No safety issues were identified. This study demonstrates that sachets offer patients suffering from migraine pain a more effective treatment with a faster onset of analgesia when compared with tablets.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Diclofenac/administration & dosage , Migraine Disorders/drug therapy , Administration, Oral , Adult , Cross-Over Studies , Female , Humans , Male , Pain/drug therapy , Tablets
2.
Cephalalgia ; 24(4): 271-9, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15030535

ABSTRACT

Migraine induces disability and an impaired quality of life, even between attacks. As most studies are based on subjective reports only, this study was set up to objectively quantify the interictal daily activities and heart rate of migraine patients, in relation to their subjectively reported highest realizable level of activity and of symptoms of mood in their habitual environment. Measurements were obtained during a migraine-free 2-day period of 24 patients (age range: 21-57 years) and 24 controls (age range: 18-59 years). Accelerometry was used to quantify the time spent in different postures and movements. The subjective parameters were documented by daily log. Whereas heart rate was similar for patients and controls, migraineurs were found to be significantly less physically active than controls and reported a significantly lower realizable level of activity. In addition, when active, their body motility was less than that of controls. Migraine patients also showed a higher level of sleepiness and lower level of vigour. These interictal behavioural and subjective phenomena objectively illustrate the individual and societal burden of migraine and its chronic impact on both domains.


Subject(s)
Activities of Daily Living/psychology , Migraine Disorders/psychology , Motor Activity/physiology , Adolescent , Adult , Aged , Female , Heart Rate , Humans , Kinetocardiography , Male , Middle Aged , Migraine Disorders/physiopathology , Posture/physiology , Quality of Life
3.
Cephalalgia ; 24(1): 52-3, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14687013

ABSTRACT

We describe a man with chronic paroxysmal hemicrania, who remained free of headaches on indomethacin, 25 mg once or twice daily. However, in this case, in contrast to typical cases of paroxysmal hemicrania, the pain of the headaches was nonlateralized and was located in the centre of the forehead. The headaches were not associated with local autonomic symptoms or signs involving the eyes or nose. Initially, the pain of the headaches lasted for seconds only and was brought on by coughing.


Subject(s)
Pain/diagnosis , Pain/etiology , Vascular Headaches/complications , Vascular Headaches/diagnosis , Adult , Cardiovascular Agents/therapeutic use , Cluster Headache/complications , Cluster Headache/diagnosis , Diagnosis, Differential , Humans , Indomethacin/therapeutic use , Male , Pain/classification , Pain/drug therapy , Treatment Outcome , Vascular Headaches/classification , Vascular Headaches/drug therapy
4.
Cephalalgia ; 22(10): 815-7, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12485208

ABSTRACT

We describe the preventive use of naratriptan, mostly as add-on to high-dose verapamil treatment, in nine patients with cluster headache. The addition of the naratriptan further improved the headaches in seven of the nine patients.


Subject(s)
Cluster Headache/prevention & control , Indoles/therapeutic use , Piperidines/therapeutic use , Adult , Aged , Cluster Headache/physiopathology , Female , Humans , Indoles/adverse effects , Male , Middle Aged , Piperidines/adverse effects , Tryptamines
SELECTION OF CITATIONS
SEARCH DETAIL
...